Dr. Tan obtained his Ph.D (2012) from National University of Singapore.  His research work focuses on the genomic profiling of Asian cancers and precision therapy for these cancers. He is committed to using high-throughput genome sequencing platform to study the genetic and epigenetic variation of high-incidence malignant tumors, combining tumor genome and clinicopathological information to discover new targeted therapies, and identifying the molecular mechanism of drug resistance in tumor therapy.

1) Identification of novel tumor suppressor genes and the governed oncogenic signaling pathways in human cancers through integrative genomic and epigenomic analysis; 2) Characterization of molecular mechanism underlying metastasis, chemoresistance and acquired resistance of targeted-therapy; 3) Investigation of the role of cancer stem cells in targeted- and chemo-therapies in different cancer model; 4) Genome-wide mapping of predictive biomarkers of drug response and patient stratification of novel targeted-therapies.

2012 Ph.D., National University of Singapore, Singapore；
2002 M.S., Xiamen University in P.R.China；
1999 B.S., Xiamen University in P.R.China .
1.Chen J, Hong JH, Huang Y, Liu S, Yin J, Deng P, Sun Y, Yu Z, Zeng X, Xiao R, Chan JY, Guan P, Wang Y, Wang P, Liu L, Wen S, Yu Q, Ong CK, Teh BT, Xiong Y, Tan J.  EZH2 mediated metabolic rewiring promotes tumor growth independently of histone methyltransferase activity in ovarian cancer. Mol Cancer. 2023 May 20;22(1):85. doi: 10.1186 (Corresponding author， IF：44.1)
2.Jinghong Chen, Zhixiang Zuo, Yan Gao, Xiaosai Yao, Peiyong Guan, Yali Wang, Zhimei Li, Zhilong Liu, Jing Han Hong, Peng Deng, Jason Yongsheng Chan, Daryl Ming Zhe Cheah, Jingquan Lim, Kelila Xin Ye Chai, Burton Kuan Hui Chia, Jane Wan Lu Pang, Joanna Koh,Dachuan Huang, Haixia He, Yichen Sun, Lizhen Liu, Shini Liu, Yuhua Huang, Xiaoxiao Wang, Hua You, Sahil Ajit Saraf, Nicholas Francis Grigoropoulos, Xiaoqiu Li, Jinxin Bei, Tiebang Kang, Soon Thye Lim, Bin Tean Teh, Huiqiang Huang, Choon Kiat Ong, Jing Tan .Aberrant JAK-STAT signaling-mediated chromatin remodeling impairs the sensitivity of NK/T-cell lymphoma to chidamide. Clin Epigenetics 2023 Feb 6;15(1) (Corresponding author, IF: 7.28)
3.Wang Y, Zhou W, Chen J, Chen J, Deng P, Chen H, Sun Y, Yu Z, Pang D, Liu L, Wang P, Hong JH, Teh BT, Huang H, Li W, Yi Z, Lim ST, Chen Y, Ong CK, Liu M, Tan J. Preclinical characterization of WB737, a potent and selective STAT3 inhibitor, in natural killer/T-cell lymphoma, MedComm (2020). 2023 Jun 16;4(4):e284.(Corresponding author)
4.Deng P, Wang Z, Chen J, Liu S, Yao X, Liu S, Liu L, Yu Z, Huang Y, Xiong Z, Xiao R, Gao J, Liang W, Chen J, Liu H, Hong JH, Chan JY, Guan P, Chen J, Wang Y, Yin J, Li J, Zheng M, Zhang C, Zhou P, Kang T, Teh BT, Yu Q, Zuo Z, Jiang Q, Liu J, Xiong Y, Xia X, Tan J. RAD21 amplification epigenetically suppresses interferon signaling to promote immune evasion in ovarian cancer. J Clin Invest. 2022 Oct 6:e159628. doi: 10.1172/JCI159628 (Corresponding author, IF:19.456)
5.Sun Y, Gao Y, Chen J, Huang L, Deng P, Chen J, Chai KXY, Hong JH, Chan JY, He H, Wang Y, Cheah D, Lim JQ, Chia BKH, Huang D, Liu L, Liu S, Wang X, Teng Y, Pang D, Grigoropoulos NF, Teh BT, Yu Q, Lim ST, Li W, Ong CK, Huang H, Tan J. CREBBP cooperates with the cell cycle machinery to attenuate chidamide sensitivity in relapsed/refractory diffuse large B-cell lymphoma.Cancer Lett. 2021 Sep2:S0304-3835(21)00438-9.doi:10.1016/j.canlet.2021.09.002. PMID: 34481935 (Corresponding author，IF:8.6)
6.Zhaoliang Yu*, Peng Deng*, Yufeng Chen*, Shini Liu2, Jinghong Chen2, Zihuan Yang3, Jianfeng Chen2, Xinjuan Fan4, Peili Wang2, Zerong Cai1, Yali Wang2, Peishan Hu3, Dezheng Lin5, Rong Xiao6, Yifeng Zou1, Yan Huang4, Qiang Yu, Ping Lan, Jing Tan#, Xiaojian Wu#. Inhibition of the PLK1-coupled cell cycle machinery overcomes resistance to oxaliplatin in colorectal cancer. Advanced Science. 28 October 2021 doi.org/10.1002/advs.202100759 (Co-corresponding author，IF：16.8)
7.Liu S, Zou Q, Chen JP, Yao X, Guan P, Liang W, Deng P, Lai X, Yin J, Chen J, Chen R, Yu Z, Xiao R, Sun Y, Hong JH, Liu H, Lu H, Chen J, Bei JX, Koh J, Chan JY, Wang B, Kang T, Yu Q, Teh BT, Liu J, Xiong Y, Tan J. Targeting Enhancer Reprogramming to Mitigate MEK Inhibitor Resistance in preclinical models of Advanced Ovarian Cancer. J Clin Invest 2021 Oct 15;131(20):e145035. doi: 10.1172/JCI145035. (Corresponding author，IF:19.456)
8.Liu L, Liu S, Deng P, Liang Y, Xiao R, Tang LQ, Chen J, Chen QY, Guan P, Yan SM, Huang X, Hong JH, Chen J, Sun Y, Teh BT, Yu Q, Mai HQ, Tan J. Targeting the IRAK1-S100A9 Axis Overcomes Resistance to Paclitaxel in Nasopharyngeal Carcinoma. Cancer Res. 2021 Mar 1;81(5):1413-1425. doi: 10.1158/0008-5472.CAN-20-2125. PMID: 33402387 （Corresponding author，IF:13.5）
9.Xing M#, Ooi WF#, Tan J#, Qamra A, Lee PH, Li Z, Xu C, Padmanabhan N, Lim JQ, Guo YA, Yao X, Amit M, Ng LM, Sheng T, Wang J, Huang KK, Anene-Nzelu CG, Ho SWT, Ray M, Ma L, Fazzi G, Lim KJ, Wijaya GC, Zhang S, Nandi T, Yan T, Chang MM, Das K, Isa ZFA, Wu J, Poon PSY, Lam YN, Lin JS, Tay ST, Lee MH, Tan ALK, Ong X, White K, Rozen SG, Beer M, Foo RSY, Grabsch HI, Skanderup AJ, Li S, Teh BT, Tan P. Genomic and epigenomic EBF1 alterations modulate TERT expression in gastric cancer. J Clin Invest. 2020 May 4. pii: 126726. doi: 10.1172/JCI126726 （Co-first，IF：19.468）
10.Nairismägi M, Gerritsen ME, Li ZM, Wijaya GC, Chia BKH, Laurensia Y, Lim JQ, Yeoh KW, Yao XS, Pang WL, Bisconte A, Hill RJ, Bradshaw JM, Huang D, Song TLL, Ng CCY, Rajasegaran V, Tang T, Tang QQ, Xia XJ, Kang TB, Teh BT, Lim ST, Ong CK, Tan J . Oncogenic Activation of JAK3-STAT Signaling Confers Clinical Sensitivity to PRN371, a Novel Selective and Potent JAK3 Inhibitor, in Natural Killer/T-cell Lymphoma Leukemia 2018 Feb 2. doi: 10.1038/s41375-017-0004 . （Corresponding author，IF：11.702）
11.Yao X*, Tan J*, Lim KJ, Koh J, Ooi WF, Li Z, Huang D, Xing M, Chan YS, Qu JZ, Tay ST, Wijaya G, Lam YN, Hong JH, Lee-Lim AP, Guan P, Ng MSW, He CZ, Lin JS, Nandi T, Qamra A, Xu C, Myint SS, Davies JOJ, Goh JY, Loh G, Tan BC, Rozen SG, Yu Q, Tan IBH, Cheng CWS, Li S, Chang KTE, Tan PH, Silver DL, Lezhava A, Steger G, Hughes JR, Teh BT, Tan P., VHL deficiency drives enhancer activation of oncogenes in clear cell renal cell carcinoma. Cancer Discov. 2017 Nov;7(11):1284-1305. doi: 10.1158/2159-8290.CD-17-0375. (Co-first, IF=39.6)
12.M-L Nairismägi, J Tan*, J Q Lim, S Nagarajan, C C Y Ng, V Rajasegaran, D Huang, W K Lim, Y Laurensia, G C Wijaya, Z M Li, I Cutcutache, W L Pang, S Thangaraju, J Ha, L P Khoo, S T Chin, S Dey, G Poore, L H C Tan, H K M Koh, K Sabai, H-L Rao, K L Chuah, Y-H Ho, S-B Ng, S-S Chuang, F Zhang, Y-H Liu, T Pongpruttipan, Y H Ko, P-L Cheah, N Karim, W-J Chng, T Tang, M Tao, K Tay, M Farid, R Quek, S G Rozen, P Tan, B T Teh, S T Lim, S-Y Tan and C K Ong, JAK-STAT and G protein-coupled receptor signaling pathways are frequently altered in epitheliotropic intestinal T-cell lymphoma. Leukemia. 2016 Feb 8. doi: 10.1038/leu.2016.13. (Co-first, IF=11.702) 
13.Tan J*, Ong CK*, Lim WK*, Ng CC, Thike AA, Ng LM, Rajasegaran V, Myint SS, Nagarajan S, Thangaraju S, Dey S, Nasir ND, Wijaya GC, Lim JQ, Huang D, Li Z, Wong BH, Chan JY, McPherson JR, Cutcutache I, Poore G, Tay ST, Tan WJ, Putti TC, Ahmad BS, Iau P, Chan CW, Tang AP, Yong WS, Madhukumar P, Ho GH, Tan VK, Wong CY, Hartman M, Ong KW, Tan BK, Rozen SG, Tan P, Tan PH, Teh BT. Genomic landscapes of breast fibroepithelial tumors. Nat Genet. 2015 Nov; 47(11):1341-5. doi: 10.1038/ng.3409 (Co-first, IF=38.33).
14.Lim WK*, Ong CK*, Tan J*, Thike AA, Ng CC, Rajasegaran V, Myint SS, Nagarajan S, Nasir ND, McPherson JR, Cutcutache I, Poore G, Tay ST, Ooi WS, Tan VK, Hartman M, Ong KW, Tan BK, Rozen SG, Tan PH, Tan P, Teh BT. Exome sequencing identifies highly recurrent MED12 somatic mutations in breast fibroadenoma. Nat Genet. 2014 Aug; 46 (8):877-80. doi: 10.1038/ng.3037 (Co-first, IF=38.33).
15.Tan J*, Yang XJ*, Jiang X, Zhou JB, Li ZM, Lee PL, Li BJ, Robson P, Yu Q.  Integrative epigenome analysis identifies a Polycomb-targeted differentiation program as a tumor suppressor event epigenetically inactivated in colorectal cancer. Cell Death Dis. 2014, 5: e1324 (Co-first, IF=8.79)
16.Tan J, Li Z, Lee PL, Guan P, Aau MY, Lee ST, Feng M, Lim CZ, Lee EY, Wee ZN, Lim YC, Karuturi RK, Yu Q. PDK1 Signaling Towards PLK1-Myc Activation Confers Oncogenic Transformation and Tumor Initiating Cell Activation and Resistance to mTOR-targeted Therapy. Cancer Discov. 2013, 3(10):1156-71. (IF=39.6)
17.Tan J#, Yu Q "Molecular mechanisms of tumor resistance to PI3K-mTOR-targeted therapy." Chin J Cancer 2013 Jul 5 ; 32(7) : 376-9 Epub 2013 May 14 (#Corresponding author)
18.Tan J, Yu Q. PDK1-driven Myc signaling regulates cellular response to mTOR inhibitors. Cell Cycle. 2011, 10(7): 1019-1020. (IF=5.006)
19.Tan J, Lee PL, Li Z, Jiang X, Lim YC, Hooi SC, Yu Q. B55β-associated PP2A complex controls PDK1-directed myc signaling and modulates rapamycin sensitivity in colorectal cancer. Cancer Cell. 2010, 18 (5): 459-71. (IF=39.407)
20.Jiang X*, Tan J*, Li J, Kivimäe S, Yang X, Zhuang L, Lee PL, Chan MT, Stanton LW, Liu ET, Cheyette BN, Yu Q. DACT3 is an epigenetic regulator of Wnt/beta-catenin signaling in colorectal cancer and is a therapeutic target of histone modifications. Cancer Cell. 2008, 13(6): 529-41. (co-first author, IF=39.407)
21.Li J*, Tan J*, Zhuang L, Banerjee B, Yang XJ, Chau JF, Lee PL, Hande MP, Li B, Yu Q.  Ribosomal protein S27-like, a p53-inducible modulator of cell fate in response to genotoxic stress. Cancer Res. 2007, 67(23): 11317-26. (co-first author, IF=9.284)
22.Tan J, Yang X, Zhuang L, Jiang X, Chen W, Lee PL, Karuturi RK, Tan PB, Liu ET, Yu Q. Pharmacologic disruption of Polycomb-repressive complex 2-mediated gene repression selectively induces apoptosis in cancer cells. Genes Dev. 2007, 21(9): 1050-63. (IF=12.639)
23.Tan J, Zhuang L, Jiang X, Yang KK, Karuturi KM, Yu Q.  Apoptosis signal-regulating kinase 1 is a direct target of E2F1 and contributes to histone deacetylase inhibitor-induced apoptosis through positive feedback regulation of E2F1 apoptotic activity. J Biol Chem. 2006, 281 (15): 10508-15. (IF=4.60)
24.Zhao Y*, Tan J*, Zhuang L, Jiang X, Liu ET, Yu Q.  Inhibitors of histone deacetylases target the Rb-E2F1 pathway for apoptosis induction through activation of proapoptotic protein Bim. Proc Natl Acad Sci U S A. 2005, 102 (44):16090-5. (co-first author, IF=9.806)
25.Tan J, Zhuang L, Leong HS, Iyer NG, Liu ET, Yu Q. Pharmacologic modulation of glycogen synthase kinase-3beta promotes p53-dependent apoptosis through a direct Bax-mediated mitochondrial pathway in colorectal cancer cells. Cancer Res. 2005, 65 (19): 9012-20. (IF=9.284)